CIBINQO (abroctinib) - a once-daily oral JAK1 inhibitor for moderate-to-severe atopic dermatitis (AD)1
Cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.1
1. Cibinqo Summary of Product Characteristics.
▼This product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare Professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions. Legal Category: S1A.
PP-CIB-IRL-0022 Date of Preparation: September 2022